https://www.tga.gov.au/periodic/covid-19-vaccine-weekly-safety-report-11-11-2021 Vaccination against COVID-19 is the most effective way to reduce deaths and severe illness from infection. The protective benefits of vaccination continue to far outweigh the potential risks. Like all medicines, COVID-19 vaccines may cause some side effects. The most frequently reported include injection-site reactions (such as a sore arm) and more general symptoms, like headache, muscle pain, fever and chills. This reflects what was seen in the clinical trials. We are carefully monitoring and reviewing reports of: myocarditis and pericarditis following mRNA vaccines, particularly in younger age groupsthrombosis with thrombocytopenia syndrome (TTS) following Vaxzevria (AstraZeneca)Guillain-Barre Syndrome (GBS) following Vaxzevria (AstraZeneca)immune thrombocytopenia (ITP) following Vaxzevria (AstraZeneca)Myocarditis is a known but very rare side effect of Comirnaty (Pfizer) and Spikevax (Moderna). It is usually temporary with most people getting better within a few days. Myocarditis is reported in about one in every 100,000 people who receive Comirnaty (Pfizer), although it is more common in young men and teenage boys after the second dose (4–7 cases per 100,000 doses). To 7 November 2021, the TGA has received 288 reports which have been assessed as likely to be myocarditis from about 22.7 million doses of Comirnaty (Pfizer). Thrombosis with thrombocytopenia syndrome (or TTS) is a very rare but serious side effect of Vaxzevria (AstraZeneca). Our analysis shows it is reported in about 2 in every 100,000 people following vaccination, although the risk is slightly higher in people under 60 years. The risk of TTS is much lower after the second vaccine dose (0.3 in every 100,000 vaccinated people).Two new cases of TTS were reported this week, taking the total to 160. Of these, 139 cases occurred after a first dose and 21 after a second dose from about 13.2 million doses of Vaxzevria (AstraZeneca).
